Evaluation of Hematological and Biochemical Parameter Changes in MDR-TB Patients Undergoing OAT Treatment at RSUD Anutapura Palu in 2022-2025
DOI:
https://doi.org/10.31004/joecy.v5i2.484Keywords:
MDR-TB, OAT, leukocytes, hemoglobin, NLR, hematocrit, platelets, SGOT, SGPT, urea, creatinineAbstract
Multidrug-resistant tuberculosis (MDR-TB) is a major challenge in the control of tuberculosis in Indonesia. Long-term treatment with anti-tuberculosis drugs (OAT) is known to cause significant side effects on hematological and biochemical functions. This study aims to evaluate changes in leukocyte count, neutrophil-lymphocyte ratio (NLR), hematocrit, platelet count, hemoglobin, SGOT, SGPT, urea, and creatinine levels in MDR-TB patients undergoing OAT treatment at RSUD Anutapura Palu during the period of 2022-2024. The research employed a retrospective cohort design using secondary data from patient medical records. The results showed a decrease in leukocytes, NLR, platelets, and hemoglobin, as well as an increase in SGOT, SGPT, urea, creatinine and hematocrit after treatment. This study emphasizes the importance of regular monitoring for OAT side effects to improve treatment effectiveness and patient safety.
References
Aristiana, Y., & Wartono, D. (2019). Risk factors for MDR-TB in pulmonary TB patients at Malang City General Hospital. Indonesian Journal of Epidemiology, 3(1), 20–28.
Fauziah, N., et al. (2015). The Effect of Isoniazid on Hematopoiesis and Sideroblastic Anemia. Indonesian Biomedical Journal.
Fregona, G., et al. (2017). Risk factors associated with multidrug-resistant tuberculosis in Espírito Santo, Brazil. Revista de Saúde Pública, 51, 41. https://doi.org/10.1590/S1518-8787.2017051006688
Kassa, D., Habte, A., & Tsegaye, A. (2016). Hematological and immunological profiles of multidrug-resistant tuberculosis patients before and after intensive phase treatment. Journal of Clinical Tuberculosis and Other Mycobacterial Diseases, 5, 18–24. https://doi.org/10.1016/j.jctube.2016.01.003
Ministry of Health of the Republic of Indonesia. (2023). Indonesia Health Profile 2023. Jakarta: Ministry of Health.
World Health Organization. (2019). WHO Consolidated Guidelines on Drug-Resistant Tuberculosis Treatment. Geneva: WHO.
World Health Organization. (2020). Global Tuberculosis Report 2020. Geneva: WHO.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 indriani, Andi Meutia Ilhamjaya, Andrini Suryana Mangopa, Tri Fadila Maharani
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
